Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

Delayed Quote. Delayed  - 10/21 10:00:15 pm
61.2 USD   -1.16%
10/22 MERCK : FDA Approves Merck’s ZINPLAVA™ (bezlotoxumab) to..
10/21 MERCK : ’s KEYNOTE-045 Studying KEYTRUDA® (pembrolizumab) in A..
10/20MERCK & CO., IN : quaterly earnings release
News SummaryMost relevantAll newsSector news 

Merck & Co., Inc. : Merck to Present at Deutsche Bank 37th Annual Health Care Conference

share with twitter share with LinkedIn share with facebook
share via e-mail
05/08/2012 | 02:15pm CEST

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Peter Kellogg, executive vice president and chief financial officer and Nancy Thornberry, senior vice president and franchise head for diabetes and endocrinology are scheduled to present at the Deutsche Bank 37th Annual Health Care Conference in Boston, Mass. on May 9 at 8:00 a.m. EDT. Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at: http://www.merck.com/investors/events-and-presentations/home.html.

About Merck

Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.merck.com and connect with us on Twitter, Facebook and YouTube.

Forward-Looking Statement

This news release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such statements may include, but are not limited to, statements about the benefits of the merger between Merck and Schering-Plough, including future financial and operating results, the combined company's plans, objectives, expectations and intentions and other statements that are not historical facts. Such statements are based upon the current beliefs and expectations of Merck's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements.

The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the possibility that all of the expected synergies from the merger of Merck and Schering-Plough will not be realized, or will not be realized within the expected time period; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; Merck's ability to accurately predict future market conditions; dependence on the effectiveness of Merck's patents and other protections for innovative products; and the exposure to litigation and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck's 2011 Annual Report on Form 10-K and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).

Ron Rogers, (908) 423-6449
Carol Ferguson, (908) 423-4465

© Business Wire 2012
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MERCK & CO., INC.
10/22 MERCK : FDA Approves Merck’s ZINPLAVA™ (bezlotoxumab) to Reduce Recu..
10/21 MERCK : ’s KEYNOTE-045 Studying KEYTRUDA® (pembrolizumab) in Advanced Blad..
10/20 MERCK : New Findings from Merck & Company Describe Advances in Clinical Trials a..
10/20 MERCK : Findings on Pneumonia Reported by Researchers at Merck & Company (Ceftol..
10/20 NEW PEPTIDE HYDROLASES STUDY RESULTS : Improving Aqueous Solubility...
10/20 MERCK : Studies from Merck Research Labs in the Area of Thrombosis Reported (Dif..
10/20MERCK & CO., INC. : quaterly earnings release
10/19 MERCK : Announces Pivotal Phase 3 Study of Letermovir, an Investigational Antivi..
10/18 MERCK : Country Club Trust Company N.a. Lowers stake in Merck & Co.
10/17 MERCK : Research Laboratories Facilities Designated as “Milestones in Micr..
More news
Sector news : Pharmaceuticals - NEC
10/20DJE.ON to Invest $500 Million in Illinois Wind Farm
10/19DJABBOTT LABORATORIES : Labs Swings to Loss After Booking Charge on Mylan Stake --..
10/19DJAbbott Labs Swings to Loss After Booking Charge on Mylan Stake
10/19DJABBOTT LABORATORIES : Labs Swings to Loss After Booking Charge on Mylan Stake
10/19DJPFIZER : J&J Brushes Off Pfizer's Challenge -- WSJ
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
10/22 FDA OKs Merck's bezlotoxumab to reduce recurrence of C. diff infection in cer..
10/21 HERE'S HOW LILLY AND MERCK ARE FARIN : Earnings Out Next Week
10/21 Why You (And Another Company) Should Buy Gilead - Dividend Sensei
10/21 Merck's Keytruda successful in late-stage bladder cancer study
10/20 The Drug Battle Coming To A Neighborhood Near You
Financials ($)
Sales 2016 39 696 M
EBIT 2016 13 597 M
Net income 2016 5 663 M
Debt 2016 5 348 M
Yield 2016 2,97%
P/E ratio 2016 30,00
P/E ratio 2017 19,78
EV / Sales 2016 4,40x
EV / Sales 2017 4,30x
Capitalization 169 231 M
More Financials
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 68,0 $
Spread / Average Target 11%
Consensus details
EPS Revisions
More Estimates Revisions
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis Chief Financial Officer & Executive Vice President
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.15.87%169 231
JOHNSON & JOHNSON10.44%310 358
ROCHE HOLDING LTD.-15.88%202 361
NOVARTIS AG-13.71%198 298
PFIZER INC.-0.31%195 193
More Results